HeartBeam, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $4.97 million, slightly higher than the $4.96 million loss recorded in the same period of the previous year. For the first half of 2025, the company’s net loss totaled $10.46 million, compared to $9.56 million for the first half of 2024. The company’s total operating expenses for the second quarter were $5.04 million, a marginal decrease from $5.09 million in the prior year, while total operating expenses for the first half increased to $10.54 million from $9.87 million.
In terms of revenue generation, HeartBeam continues to face challenges, with no material commercial revenue expected in 2025. The company’s cash and cash equivalents increased to $3.26 million as of June 30, 2025, up from $2.38 million at the end of 2024. Additionally, HeartBeam holds $1.8 million in short-term investments, bringing total liquidity to approximately $5.1 million. The company has indicated that its existing cash resources are insufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern.
Strategically, HeartBeam has made significant advancements in its product development. The company received FDA clearance for its HeartBeam System, a cable-free, ambulatory ECG device, in December 2024. In January 2025, HeartBeam filed a 510(k) application for software that synthesizes a 12-lead ECG from the device's signals. The company also announced a strategic collaboration with AccurKardia to enhance its product offerings with automated ECG interpretation capabilities. This collaboration is expected to expedite product development and improve the speed of diagnosis for arrhythmias.
Operationally, HeartBeam has made strides in its research and development efforts, with R&D expenses increasing by 17% in the second quarter compared to the previous year, driven by product development costs and an increase in headcount. The company has also initiated an Early Access Program for its HeartBeam System to gather user feedback ahead of commercialization. As of June 30, 2025, HeartBeam employed 19 individuals, reflecting a focus on maintaining a lean operational structure while preparing for future growth.
Looking ahead, HeartBeam's management remains focused on achieving critical clinical and regulatory milestones to support its commercialization plans. The company is actively seeking additional capital through equity and debt financing to sustain its operations and fund ongoing development efforts. However, management has cautioned that there is no assurance that such financing will be available on acceptable terms, which could significantly impact the company's future operations and financial condition.
About HeartBeam, Inc.
HeartBeam, Inc. develops portable, FDA-cleared cardiac monitoring devices utilizing proprietary technology to capture high-fidelity ECG signals from three directions. Its products enable remote detection and diagnosis of cardiac conditions, including arrhythmias and heart attacks, through user-friendly, cable-free hardware and cloud-based software. Targeting healthcare providers and patients, the company aims to improve early diagnosis, reduce healthcare costs, and expand advanced cardiac diagnostics outside clinical settings.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.